A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2007
At a glance
- Drugs Beclometasone; R 112
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Rigel Pharmaceuticals
- 23 Aug 2007 The expected completion date for this trial is now 1 Sep 2005.
- 24 Dec 2005 New trial record.